Conflict of interest statement: AK: Consultant: Adverum, Aerpio, Allergan, 
Chengdu Kanghong, DORC, Genentech, Inc., Kato, Kodiak, Novartis, Gemini, 
Graybug, Gyroscope, Opthea, Oxurion, PolyPhotonix, Recens Medical, Regenxbio, 
Roche Research support: Adverum, Alkahest, Allegro, Allergan, Chengdu Kanghong, 
Gemini, Genentech, Inc., Gyroscope, Iveric Bio, NGM, Neurotech, Kodiak, 
Novartis, Opthea, Oxurion, Regenxbio, Recens Medical, Roche Lecture fees: 
Allergan, Genentech, Novartis CD: Consultant: Genentech, Roche, Regeneron, 
Novartis, IvericBio Research support: Genentech, Roche, Regeneron, Novartis, 
IvericBio, Kodiak, Adverum, Gyroscope Lecture fees: Novartis, DORC CYW: 
Consultant: Allergan/AbbVie, Alcon, Alimera Sciences, Novartis, Regeneron, 
REGENXBIO, Genentech, DORC DE: Consultant: Genentech, Regeneron, Allergan, 
Novartis, Notal Vision, EyePoint, Gyroscope, Kodiak, RecensMedical, DORC, 
IvericBio, Apellis, KKR, Regenxbio, Bausch & Lomb Research support: AsclepiX, 
Genentech, Bayer, Novartis, Alimera, Opthea, Ocular Therapeutix, EyePoint, 
Mylan, Chengdu, Gemini, Gyroscope, Kodiak, NGM, RecensMedical, Alkahest, Ionis, 
IvericBio, Regenxbio Lecture fees: Genentech, Bayer, Allergan, Novartis, 
EyePoint, DORC, Apellis Equity/Stockholder: Clearside, US Retina, Hemera 
Biopharmaceuticals, Boston Image Reading Center, Network Eye Founder: Network 
Eye RPS: Consultant: Regeneron, Genentech, Alcon, Novartis, Asclepix, Gyroscope, 
Bausch and Lomb. Research support: Apellis, NGM Biopharma The authors report no 
other conflicts of interest in this work.